Life Science Partner is pleased to announce the recruitment of Peter Wehrly as Chief Executive Officer with Vivex Biologics.
Vivex Biologics is a leading regenerative medicine company that markets tissue technology products and cellular therapies focused on orthopaedic applications with an emphasis on spine related therapies. They have a diverse portfolio of current products including cellular bone matrices, amniotic tissue, general orthopaedics, and sports medicine products to meet the therapeutic demand in the areas of spine, dental, sport medicine, and wound care.
Vivex is preparing for its next stage of growth with the launch of its VIA Disc product, a paradigm-changing treatment for Degenerative Disc Disease (DDD). As the company moves into the biologics space, it sought a seasoned Chief Executive to lead the company through its next stage of growth.
Wehrly is a leader in the spine and orthobiologics industries and will help lead Vivex Biologics’ expansion of their sales force and guide the company through continued growth. He is a strategic leader with a broad background in growth and operational efficiencies within public and private companies in the medical device industry. Prior to joining Vivex, Wehrly served as Chief Executive Officer with Synaptive Medical, where he led a global team launching the 2nd generation disruptive surgical robotic technology portfolio across North America, Western Europe, and Asia.
He was also Chief Executive at PQ Bypass, where he led a cross-functional team in gaining CE Mark for their Detour System, a technology designed to advance the treatment of long-segment peripheral artery disease, and approval to embark on their PMA trial in the US and Europe.
Previously, Wehrly served as Group President for Covidien where he turned around the Respiratory and Monitoring Solutions business and was later responsible for the Vascular Therapies business. Wehrly is a seasoned executive in the spine industry having led several divisions of Medtronic including Spinal and Biologics for 8 years. He played an integral role in their global market leadership positions and saw them grow from $500M to over $2.8B in compound annual growth rate.
Wehrly will play a pivotal role in helping Vivex Biologics during its next stage of growth and development as they launch a new product in the biologics space, leveraging his expertise in the spine industry and his commercial and operational strengths to ensure continued growth and preparation for a future financing event.
About Life Science Partner
Life Science Partner is a specialized executive search firm that recruits transformational leaders for healthcare and life sciences companies. Our high-touch, partner-led process ensures an exceptional level of service, while our backgrounds as physicians and industry executives enable us to efficiently deliver the brightest candidates in the medical device, biopharmaceuticals, diagnostics, and healthcare technology fields.